<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082599</url>
  </required_header>
  <id_info>
    <org_study_id>CEP 2016-002</org_study_id>
    <nct_id>NCT03082599</nct_id>
  </id_info>
  <brief_title>Symfony Toric Intraocular Lens Visual Outcomes</brief_title>
  <official_title>Visual Outcomes of an Extended Depth of Focus (EDOF) Intraocular Lens (IOL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carolina Eyecare Physicians, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Science in Vision</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Carolina Eyecare Physicians, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In July 2016, the FDA approved an extended depth of focus (EDOF) IOL (Tecnis Symfony, Abbott
      Medical Optics) helping to improve the sharpness of vision at near, intermediate and far
      distances reducing the need of glasses after cataract surgery. It is available in both a
      non-toric version and a toric version for patients with astigmatism. The difference between
      this lens and the multifocal (MIOL) counterpart is that the EDOF, similarly to a monofocal
      IOL, has one focal point (elongated in the EDOF) while the multifocals have 2 focal points;
      therefore, having less of a halo and glare problem. Pivotal trial results where Symfony was
      compared to a monofocal IOL showed similar uncorrected distance visual acuity (UCDVA), better
      intermediate (77% vs. 34% 20/25 uncorrected intermediate visual acuity - UCIVA) and near
      vision (Symfony patients were able to read two additional, progressively smaller lines
      compared to the monofocal IOL).A One potential disadvantage of the EDOF IOL compared to a
      MIOL is the visual performance at near.B One option to deal with this potential shortcoming
      is to set the non-dominant eye for a small residual myopic error (-0.50 D)C what is referred
      to as nano-vision or mini mono-vision.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2017</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binocular distance-corrected near (40 cm) visual acuity.</measure>
    <time_frame>1 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Binocular distance-corrected near (40 cm) visual acuity.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of manifest cylinder (diopters).</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of manifest cylinder (diopters).</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uncorrected and distance-corrected near (40 cm) visual acuity</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected and distance-corrected near (40 cm) visual acuity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected and distance-corrected intermediate (66 cm) visual acuity</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected and distance-corrected intermediate (66 cm) visual acuity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected and best-corrected distance (4 m) visual acuity</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected and best-corrected distance (4 m) visual acuity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Patient-Reported Visual Symptoms Questionnaire (PRVSQ)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Patient-Reported Visual Symptoms Questionnaire (PRVSQ)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Spectacle Independence Questionnaire</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Spectacle Independence Questionnaire</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IOL orientation (in degrees) from surgery to 3 months postoperative</measure>
    <time_frame>3 months</time_frame>
    <description>Toric IOL stability from time of surgery to 3 months postoperative</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Residual mean spherical equivalent refraction</measure>
    <time_frame>1 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Residual mean spherical equivalent refraction</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Residual refractive sphere</measure>
    <time_frame>1 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Residual refractive sphere</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Residual refractive cylinder</measure>
    <time_frame>1 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Residual refractive cylinder</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of eyes with postoperative manifest refraction spherical equivalent (MRSE) accuracy to target ≤ 0.5D</measure>
    <time_frame>1 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of eyes with postoperative MRSE accuracy to target ≤ 0.5D</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cataract Bilateral</condition>
  <condition>Astigmatism Bilateral</condition>
  <arm_group>
    <arm_group_label>Emmetropia both eyes (OU) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nanovision group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Presbyopia and astigmatism correcting intraocular lens</intervention_name>
    <description>The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
    <arm_group_label>Emmetropia both eyes (OU) group</arm_group_label>
    <arm_group_label>Nanovision group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is undergoing bilateral cataract extraction with intraocular lens
             implantation.

          2. Willing and able to provide written informed consent for participation in the study

          3. Willing and able to comply with scheduled visits and other study procedures.

          4. Scheduled to undergo standard cataract surgery with topical anesthesia in both eyes
             within 6-15 days between surgeries.

          5. Subjects who require an IOL power in the range of +5.0 D to +34.0 D only.

          6. Potential postoperative visual acuity of 0.2 logMAR (20/32 Snellen) or better in both
             eyes.

        Exclusion Criteria:

          1. Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferative
             diabetic retinopathy, shallow anterior chamber, macular edema, retinal detachment,
             aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization,
             medically uncontrolled glaucoma, microphthalmos or macrophthalmos, optic nerve
             atrophy, macular degeneration (with anticipated best postoperative visual acuity less
             than 20/30), advanced glaucomatous damage, etc.

          2. Uncontrolled diabetes.

          3. Use of any systemic or topical drug known to interfere with visual performance.

          4. Contact lens use during the active treatment portion of the trial.

          5. Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.

          6. Clinically significant corneal dystrophy

          7. History of chronic intraocular inflammation.

          8. History of retinal detachment.

          9. Pseudoexfoliation syndrome or any other condition that has the potential to weaken the
             zonules.

         10. Previous intraocular surgery.

         11. Previous refractive surgery.

         12. Previous keratoplasty

         13. Severe dry eye

         14. Pupil abnormalities

         15. Subject who may reasonably be expected to require a secondary surgical intervention at
             any time during the study (other than yttrium aluminum garnet (YAG) capsulotomy, i.e.
             LASIK)

         16. Anesthesia other than topical anesthesia (i.e. retrobulbar, general, etc).

         17. Any clinically significant, serious or severe medical or psychiatric condition that
             may increase the risk associated with study participation or may interfere with the
             interpretation of study results.

         18. Participation in (or current participation) any ophthalmic investigational drug or
             ophthalmic device trial within the previous 30 days prior to the start date of this
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerry D. Solomon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Carolina Eyecare Physicians, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helga P Sandoval, MD, MSCR</last_name>
    <phone>8438813937</phone>
    <email>helga.sandoval@carolinaeyecare.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Associated Eye Care</name>
      <address>
        <city>Stillwater</city>
        <state>Minnesota</state>
        <zip>55082</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Johnson</last_name>
      <phone>651-275-3077</phone>
      <email>pjohnson@associatedeyecare.com</email>
    </contact>
    <investigator>
      <last_name>Stephen S Lane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Long Island</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimbel Martin</last_name>
      <email>kmartin@ocli.net</email>
    </contact>
    <investigator>
      <last_name>Eric Donnenfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Eyecare Physicians, LLC</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helga P Sandoval, MD, MSCR</last_name>
      <phone>843-881-3937</phone>
      <email>helga.sandoval@carolinaeyecare.com</email>
    </contact>
    <investigator>
      <last_name>Kerry D Solomon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jefrrey F Hood, OD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Berdine Burger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slade &amp; Baker Vision Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chadisty Pauly, B.S., C.O.A</last_name>
      <phone>713-626-5544</phone>
      <email>chad@visiontexas.com</email>
    </contact>
    <contact_backup>
      <last_name>Beverly Socop, B.S.</last_name>
      <phone>(713) 626-5544</phone>
      <email>beverly@visiontexas.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Slade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bennet Walton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

